Hims & Hers Signs GLP-1 Agreement with Lilly; Shares Rise
📊 HIMS — Piyasa Yorumu
▲ up · 62%Hims & Hers' GLP-1 agreement with Eli Lilly is a positive catalyst in terms of reliable supply and revenue visibility in the weight management segment. However, the stock closed at 25.42, slightly below its 20-day SMA (25.59) and notably below its 50-day SMA (27.03); the medium-term trend remains weak. RSI at 47 is in neutral territory, while MACD is negative but close to its signal line; there is limited potential for a momentum recovery. The news could trigger an upward reaction in the short term, but breaking through the 25.6-26.0 resistance zone is critical for confirmation. I therefore see the direction as upward but keep confidence at a moderate level.
📊 LLY — Piyasa Yorumu
▲ up · 55%Hims & Hers's GLP-1 agreement with Lilly represents a new distribution channel and demand access for Lilly; the news could have a mildly positive short-term impact on the stock. However, the technical picture is weak: the price is below the SMA20 and SMA50, the RSI at 38 places it in seller territory, and the MACD is negative. After a 3% drop over 24 hours, the news could trigger a relief rally, but there is not yet confirmation of a trend reversal. Therefore, I assess the direction as 'up,' but keep confidence medium-low; unless the 1400-1405 resistance zone is broken, the upside may remain limited.